103results about How to "Improve insulin resistance" patented technology

A method of providing blood glucose therapy for a critically ill patient includes calculating a baseline nutrition feed requirement based on an algorithm that incorporates at least one of age, gender, and body size of the patient: determining a first blood glucose level; determining a second blood glucose level after a preselected time interval: determining a first body temperature reading: comparing the blood glucose levels: and administering either nutrition or insulin. The amount of nutrition administered to the patient is based on a first change in blood glucose level, the current body temperature reading, and a predetermined feed algorithm based on the second blood glucose level as well as the baseline nutritional feed requirement. The amount of insulin administered is based on a second change in blood glucose level, body temperature, and a predetermined insulin algorithm that incorporates at least one of the patient's body frame size, age, and gender.

The invention relates to the use of angiotensin II receptor antagonists for treating people in whom type 2 diabetes mellitus has been diagnosed or who are suspected of prediabetes, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure.

Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.

It is intended to provide compositions and foods for use in the treatment, prophylaxis, or amelioration of diseases or symptoms which can be treated, prevented or ameliorated by activating PPAR, in particular, insulin resistant diabetes and hyperlipidemia. Namely, medicinal compositions usable in treating, preventing or improving diseases or symptoms which can be treated, prevented or ameliorated by activation PPAR which contain humulones, isohumulones or lupulones or pharmaceutically acceptable salts or solvates thereof.

There is provided in accordance with an exemplary embodiment of the invention a method of treating diabetic patients comprising measuring a triglyceride level in a diabetic patient and applying a diabetes treatment according to the triglyceride level. Optionally, there is provided a method of screening. Alternatively or additionally, there is provided a method of weight loss. Alternatively or additionally, there is provided a method of relatively reducing HOMA-IR levels. Alternatively or additionally, there is provided a method of relatively reducing blood pressure. An exemplary device to apply the treatment is described.

The present invention relates to a health care product, in particular to a post meal glucose-stabilized convenient nutrition conjee and the preparation method thereof, which can stabilize the blood glucose after meal. The present invention provides a convenient nutrition conjee which can stabilized the blood glucose after meal, wherein the brown rice and buckwheat rice in the prescription keep the nutritious elements and the fibers to the largest extent, while the rutin and chlorophyll contained in the buckwheat rice is what the other corn corps lack, and the minerals and the vitamins of the buckwheat rice are also higher than the level of the other crops, wherein based on the medical research, the flavone of the buckwheat rice has multiple functions of anti-oxidation, decrease blood glucose, and decrease blood lipid. The post meal glucose-stabilized convenient nutrition conjee provided by the present invention can balance the nutrition, act against oxidization, meliorate the insulin resistance, decrease the dosage of the glucose-lowering drugs, improve the insulin utilization rate of the patient, effectively improve the level of oral glucose tolerance test (OGTT) and the level of glycated haemoglobin (HbALC), improve the quality of life of the patient, prevent from the complications, and be in favor of the intake by the diabetes patient.

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element. The catheter is introduced into the patient, and target tissue is treated with the at least one treatment element. The target tissue comprises mucosal tissue of the small intestine, and the medical procedure can be configured to treat one or more diseases or disorders based on a measured physiologic parameter of the patient.

A novel thyroid like compounds of formula (I), wherein R1, R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition and use thereof. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions including obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.

The present invention provides a novel carboxylic acid derivative, a salt thereof or a hydrate of them which is useful as an insulin sensitizer, and a medicament comprising the derivative as the effective ingredient. More specifically, it provides a carboxylic acid compound represented by the formula (I), a salt thereof or a hydrate of them. 1 In the formula, Ar represents a 6- to 14-membered aromatic ring group which may have at least one substituent; R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a C.sub.1-6 alkyl group or a C.sub.1-6 alkoxy group; X represents an oxygen atom or a methylene group; Y represents a group represented by the formula (II) or (III): 2 (wherein Z represents a group represented by the formula (IV): 3 (wherein R.sup.9, R.sup.10, R.sup.11 and R.sup.12 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a C.sub.1-6 alkyl group or a C.sub.1-6 alkoxy group)); m is 0 or 1; and n is 0 or 1.

α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances insulin signal transduction and increase whole-body insulin sensitivity. Therefor, AHSG and its gene(s) are useful targets for agents that inhibit the development or progression of Type II diabetes or any disease or disorder associated with increased insulin resistance. Provided herein is a method for inhibiting the biological activity of AHSG protein in a cell using compounds that inhibit phosphorylation of AHSG. Also disclosed is a method of augmenting the phosphorylation or IR-TK activity in a liver or muscle cell by providing a compound that lowers the amount of active AHSG or inhibits the biological activity of AHSG. Such effects may be achieved by delivering an antisense nucleic acid construct that hybridizes with AHSG encoding DNA. This invention includes a method (a) treating a subject that is susceptible to, or suffers from, obesity and insulin resistance or (b) increasing insulin sensitivity, and thereby preventing or treating insulin resistance in the subject. The method comprises lowering the amount of active AHSG or inhibiting the biological activity of AHSG in the subject, preferably in liver or muscle, by using AHSG antisense constructs or an anti-AHSG antibody. In a subject eating a high fat diet, the effect on body weight gain and / or insulin resistance is diminished, and total body fat content is lowered, by lowering the amount of active AHSG or inhibiting the action of the AHSG in the subject using the agents noted above.

Disclosed are a method for activating lipid metabolism in the small intestine epithelium and also a method for promoting accumulation of fatty acids into the small intestine epithelium, each of which features administering an effective amount of a diacylglycerol. Also disclosed are methods for improving various symptoms in diabetes, which have ingesting a diacylglycerol. Ingestion of the diacylglycerol leads to accumulation of the fatty acids in the small intestine. The fatty acids so accumulated promote induction of beta-oxidation, thereby not only activating lipid catabolism but also making it difficult to allow lipids to accumulate as triacylglycerols. This series of actions eventually results in development of lowering action for blood remnant-like lipoprotein level and also lowering action for blood leptin level, and hence, lipid metabolism is improved. Further, energy consumption is enhanced by promoting the induction of beta-oxidation and activating lipid catabolism.

A bathtub apparatus is provided, including a nanobubble and / or nanosized medical component generating section to combine at least either of nanobubbles or a nanosized medical component with bath water from a bathtub and to circulate the bath water to the bathtub.

A heteroaryl derivative of the formula (1):(wherein Ring Z is an optionally substituted heteroaryl, R1 is a carboxyl group or an alkoxycarbonyl group, etc., W1 and W2 are an optionally substituted lower alkylene, Ar1 is an optionally substituted arylene or an optionally substituted heteroarylene, W3 is a single bond, a lower alkylene, a lower alkenylene, etc., W4 is a single bond, —NR10—, etc., Ar2 is an optionally substituted aryl or an optionally substituted heteroaryl), or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

The invention discloses lactobacillus rhamnosus CCFM1060, a fermented food and a preparation method of a bacterial agent; increase of the abundance of Proteus induced by high lipid and high cholesterol diet is significantly reduced, and the occurrence of diseases such as urinary tract blockage, intestinal bacterial migration and enteritis is reduced; the lipid metabolism disorder of NAFLD patientsis significantly improved; insulin resistance of NAFLD mice is significantly improved; increase of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase in serum can be re-adjusted; theconcentration of low-density lipoprotein cholesterol is significantly reduced, and the risk of cardiovascular disease is reduced; the level of SOD in liver of NAFLD patients can be significantly improved; the inflammation of liver can be significantly improved; the damage of liver tissues of the NAFLD patients can be significantly improved; the expression of an Nrf2 gene in fatty liver cells can be significantly improved; the ability to absorb perfluorooctanoic acid in vitro is strong.

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and / or glycemic control agents.

The present invention describes the identification and isolation of chromones and novel chromone compositions from plant sources that exhibit up-regulation of adiponectin production by adipocytes and the normalization of virtually hundreds of genes related to glucose and fatty acid metabolic and signaling pathways. The chromone compositions are effective in enhancing adiponectin production by adipocytes and regulating genes involved in fatty acid biosynthesis, mitochondrial β-oxidation of fatty acids, steroid biosynthesis, gluconeogenesis, fat transport, PPARα / RXRα liver signaling and xenobiotic metabolism. The chromone compositions can be used to increase insulin sensitivity, improve glucose tolerance, lower triglyceride levels and balance glucose levels in mammals. Included in the present invention are methods for the prevention and treatment of a variety of diseases and conditions including, but not limited to insulin resistance, glucose intolerance, hyperglycemia, metabolic syndromes, dyslipidemia, and hypertriglyceridemia.

The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and / or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ.A compound having the general formula (I):whereinR1 represents a C1-C6 alkyl group, a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R2 represents a C1-C6 alkyl group; R3 represents a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; Q represents a group represented by the formula ═CH— or a nitrogen atom; and Substituent Group a represents a halogen atom, a C1-C6 alkyl group, a C1-C6 hydroxyalkyl group, and the like, or a pharmacologically acceptable salt thereof.

The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved.

An adiponectin enhancer comprising as an active ingredient sesamin and / or episesamin, or an analogue thereof.

A class of N-cyclohexylaminocarbonyl benzenesulfonamide derivatives are agonists or partial agonists or antagonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

A novel pyrrole derivative represented by the following formula (1) and a salt thereof: wherein R<1 >means substituted alkenyl, etc.; R<2 >means substituted benzoyl, etc.; and R<3 >to R<5 >each means hydrogen, alkyl, halogeno, etc. The derivative and salt have antidiabetic activity.

The present invention provides novel carboxylic acid derivatives useful as an insulin sensitizer, a salt thereof or a hydrate of them, and a medicament comprising the derivative as the active ingredient. Specifically, it provides a carboxylic acid derivative represented by the following formula (I):(wherein Y, L, X, T, Z, U, M and W are defined in the specification) and a salt thereof, and ester thereof or a hydrate of them.

To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance, or improve the pathosis, the present invention provides an agent or a food or drink which contains a compound having a cyclolanostane skeleton, or an organic solvent extract, a hot water extract of a plant of the family Liliaceae or Gramineae, or a fraction thereof which contains the compound as an active ingredient.